www.MarketResearchReports.com

PharmaPoint: Ulcerative Colitis

- Global Drug Forecast and

Market Analysis to 2022

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

www.MarketResearchReports.com

Introduction to Report

Launch Date: February 28, 2014

Number of Pages: 328

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 9,995

Price For Site User License: USD 19,990

Price For Global User License: USD 29,985

Delivery Time: Within 24 Hours (During Working Days)

www.MarketResearchReports.com

About the Report

During the forecast period from 2012–2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

www.MarketResearchReports.com

Research Finding

The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012 to approximately $6.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 4.7%, according to a new report from research and consulting firm by Publisher.

Johnson & Johnson (J&J) has been continually dominating the UC market due to the success of Remicade. However, Remicade’s patent is set to expire between 2015 and 2018, which will knock J&J’s sales down from approximately $2 billion in 2012 to $1.5 billion by 2022, according to Publisher.

Another key player in the UC industry, AbbVie’s Humira, will also lose its patent during the forecast period, with sales slipping from $1.2 billion in 2012 to $569 million by 2022.

However, the UC market will receive a major boost with the entry of J&J’s Simponi and Takeda’s Entyvio, with sales expected to reach an estimated $576 million and $1.3 billion by 2022, respectively.

www.MarketResearchReports.com

Scope

Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs.

Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

www.MarketResearchReports.com

Reasons to Buy

Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

www.MarketResearchReports.com

Report Coverage

1. Table of Contents2. Introduction3. Disease Overview4. Epidemiology5. Disease Management6. Competitive Assessment7. Opportunity and Unmet Need8. Pipeline Assessment9. Current and Future Players10.Market Outlook11.Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.

www.MarketResearchReports.com

Company Coverage

1. Johnson & Johnson

2. AbbVie

3. Takeda Pharmaceuticals

4. Warner Chilcott

5. Salix Pharmaceuticals/Santarus

6. Shire Pharmaceuticals

7. Ferring Pharmaceuticals

8. Pfizer

9. InDeX Pharmaceuticals

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.

www.MarketResearchReports.com

Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

www.MarketResearchReports.com

How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/ZSj

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : info@marketresearchreports.comPhone: +1 302-703-7787 (USA) +91-8762746600 (India)